Latest News for: mc4r

Edit

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

PR Newswire 31 Mar 2025
Novel next-generation MC4R long-acting peptides and oral small molecules ... The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1/GIP tirzepatide treatment.".
Edit

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin ...

Victoria Advocate 25 Mar 2025
Initiated IND-enabling toxicology programIND submission planned for 4Q25; Clinical data expected in 1H26 ....
Edit

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

PR Newswire 25 Mar 2025
"This FDA orphan designation is a key step in developing Palatin's MC4R receptor agonists for rare obesity conditions," said Carl Spana, Ph.D., President and CEO of Palatin ... patient stratification aimed at MC4R agonist treatment.
  • 1
×